ActiVein develops a patented, dual-action peripheral intravenous (IV) catheter that aims to replace the standard conventional "hospital IV line" by enabling both fluid infusion and blood withdrawal using the same venous inlet whereas the currently used devices allow, regularly, fluid infusion only.

An IV catheter is inserted in at least one vein of most patients throughout the world upon hospitalization for the delivery of fluids,medications and blood or its components to the patient's blood stream. Due to various physiological and biological reasons, drawing blood samples cannot be done through the same catheter. As a result, at least once daily, the patient is subjected to puncturing in other areas in the course of routine blood drawing rounds for laboratory tests sampling. This routine is a costly, labor-intensive, time consuming and risky procedure, subjecting patients to pain and complications such as hematomas, local infections and at times systemic infections, as well as healthcare workers to the threats of needlestick injuries, exposing them to infectious diseases such as several types of Hepatitis and HIV. 

Elimination of a major portion of needlestick punctures will result in large cost savings of needles, labor, compensation, liability, and other associated costs added to the treatment of healthcare workers exposed to infectious diseases following needlestick injuries.

Based on published research, US market for IV catheters totaled US$685 million in 2004 and was expected a growth of 8.5% to reach just above US$1 billion in 2009. The costs in the US that associated with catheter-related accidents are estimated at $400m annually.

In Q209 Activein preformed successfully a few sessions of animal trials. A facility for small scale production was built. The ActiVein IV catheter is currently undergoing final design stages. The company is about to start clinical trials. Patent approval was received under the name "Vascular Coupling Device" No 03710201.9 in the European patent office and has been registered in major countries in Europe.

The US patent and Trademark office sent recently a notice of allowance for registration of patent for "Vascular Coupling Device" Application No. 10/509.348.

Activein was founded with Xenia in 2006, matured incubator in 2008, raised additional funds and performed reverse merge to a US company to be listed in Nasdaq Stock Exchange.

TEAM

Adi Plaschkes, Co-Founder, CEO
Bsc. in Mechanical Engineering, over 20 years of experience in medical device development and invention.

Dr. Yoav Paz, MD., Co-founder, CMO
Senior surgeon at Hadassah-Hebrew University Medical Center in Jerusalem has been involved in other novel ideas in the medical field, some of which have been commercially implemented.

Ilan Shalev, Board Member, Co-Founder, CTO
Bsc. in Mechanical Engineering from Tel Aviv University. Vast experience in product development in general with specialization in medical devices. Owner of Elad Engineering, a leading development and engineering company for design of various products.

Anat Segal, Board Member, Xenia Venture Capital CEO

Boaz Dor, Board Member, Co-founded a publicly traded defense technology company, Security Devices International Inc. 

Eitan Kyiet, LLB, Board Member, Director, global supply chain and strategic alliances, Lumenis Ltd. 

www.activein.co.il